Thrombolysis in acute ischaemic stroke

Postgraduate Medical Journal

Volumn 77, Issue 905, 2001, Pages 166-171

  Pereira, A C ^a   Martin, P J ^b   Warburton, E A ^b  

^a IPSWICH HOSPITAL   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; PLACEBO; STREPTOKINASE;

BRAIN ANGIOGRAPHY; BRAIN BLOOD FLOW; BRAIN HEMORRHAGE; CHRONOPHARMACOLOGY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG SAFETY; FIBRINOLYTIC THERAPY; HUMAN; HUMAN CELL; HUMAN TISSUE; META ANALYSIS; NONHUMAN; RANDOMIZED CONTROLLED TRIAL; REVIEW; STROKE;

ACUTE DISEASE; CEREBROVASCULAR ACCIDENT; HUMANS; MAGNETIC RESONANCE ANGIOGRAPHY; RANDOMIZED CONTROLLED TRIALS; STREPTOKINASE; THROMBOLYTIC THERAPY; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TREATMENT OUTCOME;

EID: 0035096392     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pmj.77.905.166     Document Type: Review

References (62)

1. Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke
2. Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17187 of acute myocardial infarction
3. Recombinant human tissue-type plasminogen activator therapy in acute thromboembolic stroke
4. The beneficial effect of intracarotid urokinase on acute stroke in the baboon model
5. Tissue plasminogen activator. Reduction in neurologic damage after experimental embolic stroke
6. Tissue plasminogen activator-mediated thrombolysis of cerebral emboli and its effect on haemorrhagic infarction in rabbits
7. Incidence of cerebral haemorrhage after antifibrinolytic treatment for embolic stroke in rabbits
8. Thrombolysis with fibrinolysin in cerebral arterial occlusion
9. Penumbral tissues salvaged by reperfusion following middle cerebral artery occlusion in rats
10. Urgent therapy for stroke. Part I. Pilot study of tissue plasminogen activator administered within 90 minutes
11. Urgent therapy for stroke. Part II. Pilot study of tissue plasminogen activator administered 91-180 minutes from onset
12. Tissue plasminogen activator for acute ischemic stroke
13. Streptokinase for acute ischaemic stroke with relationship to time of administration
14. Randomised controlled trial of streptokinase, aspirin and combination of both in treatment of acute ischaemic stroke
15. Thrombolytic therapy with streptokinase in acute ischemic stroke
16. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke
17. Randomised double-blind placebo controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II)
18. Recombinant tissue-type plasminogen activator (alteplase) for ischaemic stroke 3 to 5 hours after symptom onset
19. Trials of streptokinase in severe acute ischaemic stroke
20. The International Stroke Trial (IST): A randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic stroke
21. Effects of tissue plasminogen activator for acute ischaemic stroke
22. Systematic review of evidence on thrombolytic therapy for acute ischaemic stroke
23. Thrombolytic therapy versus control in acute ischaemic stroke
24. Intravenous tissue-type plasminogen activator for treatment of acute stroke. The standard treatment with alteplase to reverse stroke (STARS) study
25. Can simple questions assess outcome after stroke?
26. Use of tissue-type plasminigen activator for acute ischaemic stroke
27. Should thrombolytic therapy be the first-line treatment for acute ischemic stroke? Thrombolysis - Not a panacea for ischemic stroke
28. Classification and natural history of clinically identifiable subtypes of cerebral infarction
29. Safety and efficacy of intravenous tissue plasminogen activator and heparin in acute middle cerebral artery stroke
30. Type and extent of hemispheric brain infarctions and clinical outcome in early and delayed middle cerebral artery recanalization
31. PROACT: A phase II randomised trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke
32. Hemorrhagic transformation within 36 hours of a cerebral infarct. Relationships with early clinical deterioration and 3 month outcome in the European Cooperative Acute Stroke Study (ECASS I) cohort
33. Ischaemic damage of brain microvessels: Inherent risks for thrombolyric treatment in stroke
34. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. The NINDS t-PA Stroke Study Group
35. Is visible infarction on computed tomography associated with an adverse prognosis in acute ischaemic stroke?
36. Open trial of intravenous tissue plasminogen activator in acute carotid territory stroke. Correlations of outcome with clinical and radiological data
37. Thrombolysis with intravenous rtPA in a series of 100 cases of acute carotid territory stroke: Determination of etiological, topographic, and radiological outcome factors
38. Generalized efficacy of t-PA for acute stroke. Subgroup analysis of the N1NDS t-PA Stroke Trial
39. Diagnosis of acute cerebral infarction: Comparison of CT and MR imaging
40. Comparison of clinical and neuroradiological findings in first ever stroke: A population based study
41. Magnetic resonance versus computed tomographic imaging in acute stroke
42. Ischaemic penumbra and neuronal death: Comments on the therapeutic window in acute stroke with particular reference to thrombolytic therapy
43. 14C iodoantipyrine for normal and low cerebral blood flow states in baboons
44. Pathophysiology of acute cerebral ischaemia: PET studies in humans
45. Prolonged persistence of substantial volumes of potentially viable brain tissue after stroke: A correlative PET-CT study with voxel-based data analysis
46. Treatment of acute ischemic stroke. Challenging the concept of a rigid and universal time window
47. Nuclear magnetic resonance methods in stroke
48. Clinical aspects of DWI
49. New magnetic resonance techniques for acute ischemic stroke
50. Magnetic resonance imaging of acute stroke
51. Proton spectroscopy in vivo
52. Diffusion nuclear magnetic resonance imaging in experimental stroke. Correlation with cerebral metabolites
53. Clinical outcome in ischemic stroke predicted by early diffusion-weighted and perfusion magnetic resonance imaging: A preliminary analysis
54. Diffusion-weighted magnetic resonance imaging in acute stroke
55. Measurement of infarct size using MRI predicts prognosis in middle cerebral artery infarction
56. Prediction of stroke outcome with echoplanar perfusion- and diffusion-weighted MRI
57. Measurement of initial N-acetyl aspartate concentration using magnetic resonance spectroscopy and initial infarct volume using MRI predicts outcome in patients with middle cerebral artery territory infarction
58. Diffusion-weighted imaging studies of cerebral ischaemia in gerbils
59. Enlargement of human cerebral ischaemic lesion volumes measured by diffusion weighted magnetic resonance imaging
60. Expanding the window for thrombolytic therapy in acute stroke. The role of acute MRI for patient selection
61. Intravenous tissue plasminogen activator for acute ischemic stroke; feasibility, safety, and efficacy in the first year of clinical practice
62. Early intravenous thrombolysis for acute ischemic stroke in a community-based approach